Personalized and Precision Medicine Journal

Abstract Cancer is a catastrophic illness with a significant worldwide fatality rate, anticipated to rise in the next years. Contemporary treatment modalities, including chemotherapy and radiation therapy, include constraints such as adverse effects, inconsistent efficacy, elevated expenses, and restricted accessibility. Bacteriophages have arisen as multifaceted instruments in bioengineering, with significant promise in tissue engineering, vaccine formulation, and immunotherapy. Bacteriophages are being used extensively in several fields of biotechnology and medicine, with cancer treatment being the most compelling application. Numerous studies are increasingly validating the effectiveness and safety of phage-based vectors as systemic delivery vehicles for therapeutic genes and medicines in cancer treatment. Moreover, the genetic composition of phages may be used for the creation of innovative DNA vaccines and antigen display systems, since they provide a highly structured and repeated presentation of antigens to immune cells. Bacteriophages have created novel opportunities for the precise targeting of certain molecular determinants in cancer cells. Phages may serve as anticancer agents and as carriers for imaging compounds and medicines. This article introduces bacteriophage and examines the performance of bacteriophages and bacteriophage engineering in targeted cancer treatment.

Abstract Pharmacogenomics is a relatively new subject that utilizes genomics and pharmacology to investigate the ways in which genetic variants influence individual responses to treatment with pharmaceuticals. A departure from the conventional "one-size-fits-all" treatment strategy is marked by the advent of pharmacogenomics, which makes it possible to tailor pharmacological regimens to the specific genetic profile of an individual. Significant improvements in pharmacological efficacy, reductions in adverse drug reactions (ADRs), and assistance in the development of drugs that are both safe and effective for a wide range of conditions are all possible outcomes of this domain. The purpose of this study is to investigate the prospective results of pharmacogenomics, with a particular emphasis on the function it plays in the process of drug development and its incorporation into personalized medicine. The purpose of this study is to investigate the genetic characteristics that influence the metabolism, efficacy, and toxicity of drugs, as well as to investigate the regulatory framework that is associated with pharmacogenomics testing. This paper provides a synopsis of the most important genes that are involved in pharmacogenomic responses, as well as a discussion of the potential difficulties that may arise in their practical use and the anticipated breakthroughs in this area of study.